Contact Information:
981090 Nebraska Medical Center
Omaha, NE 68198-1090
Phone: (402) 559-4287
Fax: 402-559-4907
Email: ehermsen@nebraskamed.com

Education

2004, M.B.A., University of Minnesota Carlson School of Management, Minneapolis, Minnesota
2001, Pharm.D., University of Nebraska Medical Center College of Pharmacy, Omaha, Nebraska

Postdoctoral Training

7/02 - 6/04
Fellowship in Infectious Diseases
University of Minnesota College of Pharmacy
Minneapolis, Minnesota

7/01 - 6/02
Pharmacy Practice Residency The Nebraska Medical Center Omaha, Nebraska

Current Position

• Antimicrobial Specialist & Research Associate, The Nebraska Medical Center
  
• Adjunct Assistant Professor, Department of Pharmacy Practice, University of Nebraska Medical Center College of Pharmacy
• Adjunct Assistant Professor, Section of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center College of Medicine

Recent Grant Funding

• 2007 University of Nebraska Medical Center, College of Medicine, Faculty Educational Support Grant "Development of a Web-based Educational Program in Antimicrobial Stewardship." $5,000. Co-PI: E D Hermsen, M E Rupp.
• 2006 American College of Clinical Pharmacy, "Outcomes of a Pharmacist-Initiated Step-Down Protocol for Antimicrobials." P.I.: E.D. Hermsen.

Honors & Awards

• 2008 Focused Investigator Training (F.I.T.) Program, American College of Clinical Pharmacy (selected to attend by peer review of research grant proposal)
• 2007 Preceptor of the Year Award, The Nebraska Medical Center Residency Program (selected by Post-Graduate Year One residents)
• 2007 Honorary Member of Phi Lambda Sigma Pharmacy Leadership Society (selected by University of Nebraska Medical Center College of Pharmacy students)
• 2006 Frontiers Career Development Research Award, American College of Clinical Pharmacy
• 2003 Fellowship Research Award (Best Abstract), Sixth Annual International Conference of Infectious Diseases Pharmacotherapy
• 2001 Rho Chi Achievement Award
• 2001 Pfizer Outstanding Leader Award

Membership in Professional Societies

• Infectious Diseases Society of America (Member)
• Society for Healthcare Epidemiology of America (Member)
• American Society of Microbiology (Member)
• Society of Infectious Diseases Pharmacists (Member, Membership Committee 2008, Antimicrobial Stewardship Task Force 2007, ID-trained Pharmacist Task Force 2006, Elections Committee 2005)
• University of Nebraska College of Pharmacy Alumni Association (Member, Board of Directors 2005 - 2008, President 2006 - 2007, Treasurer 2005 - 2006)
• American College of Clinical Pharmacists (Member, Infectious Diseases Practice Research Network, Secretary/Treasurer 2007 - 2008)
• Nebraska Antibiotic Resistance Awareness and Action Coalition (Member, Consumer Education Committee)
• Nebraska Immunization Registry Coalition (Member, Strategic Planning Subgroup)

Professional Certification

Board Certified Pharmacotherapy Specialist with Added Qualifications in Infectious Diseases, Board of Pharmaceutical Specialties (conferred in 2007)

Publications

Articles

• Hermsen ED, Shull SS, Parizek L, Qiu F, Wilderman J, Rupp ME. Outcomes of a pharmacist-initiated step-down protocol for antimicrobials. (Submitted 2008)
• Hermsen ED, Shull SS, Klepser DG, Iwen PC, Armbrust A, Garrett J, Freifeld AG, Rupp ME. Pharmacoeconomic Analysis of Microbiologic Techniques for Differentiating Staphylococci Directly from Blood Culture Bottles. Journal of Clinical Microbiology (In press).
• Hermsen ED, Shull SS, Mitropoulos IF, Puumala SE, Rupp ME. Prospective Evaluation of Clinical and Economic Outcomes Associated with Treatment of Serious Infections due to Gram-positive Cocci. Infectious Diseases in Clinical Practice (In press).
• Hermsen ED, Shull SS, Puumala SE, Rupp ME. Improvement in clinical and economic outcomes associated with the introduction of a standardized approach for surgical antimicrobial prophylaxis. Infection Control and Hospital Epidemiology. 2008;29:457-61.
• Hermsen ED, Garr M, Reisbig K, Friedig W, Maiefski M, Walker R, Rupp ME. CA-MRSA is thriving in Nebraska. Physicians Bulletin. 2007 (November/December), page 9.
• Hermsen ED, Garr M, Reisbig K, Maiefski M, Walker R, Rupp ME. CA-MRSA is thriving in Nebraska. Cornhusker Family Physician. 2007;53:54-5.
• Hermsen ED, Hovde LB, Konstantinides GN, Rotschafer JC. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrobial Agents and Chemotherapy. 2005;49(4):1633-5.
• Hermsen ED, Hovde LB, Sprandel KA, Rodvold KA, Rotschafer JC. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2005;49(2):685-9.
• Hotchkiss JR, Hermsen ED, Hovde LB, Simonson DA, Rotschafer JC, Crooke PS. Dynamic analysis of peritoneal dialysis associated peritonitis. ASAIO Journal. 2004;50:568-76.
• Ibrahim KH, Gunderson BW, Hermsen ED, Hovde LB, Rotschafer JC. Pharmacodynamics of pulse dosing versus standard dosing: metronidazole in vitro activity against Bacteroides fragilis and Bacteroides thetaiotamicron. Antimicrobial Agents and Chemotherapy. 2004;48(11):4195-9.
• Hermsen ED, Wynn HE, McNabb JC. Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy. American Journal of Health-System Pharmacy. 2004;61(3):245-56.
• Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: Pharmacology, Pharmacokinetics, Pharmacodynamics, and Clinical Applications. Infectious Disease Clinics of North America. 2003;17(3):545-62.
• Hermsen ED, Dandekar PK, Nightingale CH. Methicillin-resistant Staphylococcus aureus: a pathogen transitioning from the hospital to the community. Journal of Infectious Disease Pharmacotherapy. 2003;6(2):39-57.
• Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrobial Agents and Chemotherapy. 2003;47(12):3764-7.
• Hovde LB, Rotschafer SE, Ibrahim KH, Gunderson B, Hermsen ED, Rotschafer JC. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Diseases. 2003;45(4):265-7.

Chapters

• Hermsen ED, Rupp ME. Influenza. In: Pharmacotherapy: A Pathophysiologic Approach, 7th edition. Editors: JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey. McGraw-Hill, Columbus, OH. In press.
• Mitropoulos IM, Hermsen ED, Shaffer J, Rotschafer JC. Central Nervous System Infections. In: Pharmacotherapy: A Pathophysiologic Approach, 7th edition. Editors: JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey. McGraw-Hill, Columbus, OH. In press.
• Hermsen ED, Jalali Z. Gastrointestinal Infections. In: Pharmacotherapy Principles & Practice, 1st edition. Editors: MA Chisholm, JM Kolesar, PM Malone, TL Schwinghammer, BG Wells, JC Rotschafer. McGraw-Hill, Columbus, OH. Chapter 73, 2007.
• Hermsen ED, Rotschafer JC. Metronidazole and Clindamycin for Anaerobic Infections. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 2nd edition. Editors: CH Nightingale, PG Ambrose, T Murakawa, GL Drusano. Informa Healthcare USA, Inc., New York, NY. Chapter 11, 2007.
• Hermsen ED, Ross GH, Rotschafer JC. Glycopeptide Pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 2nd edition. Editors: CH Nightingale, PG Ambrose, T Murakawa, GL Drusano. Informa Healthcare USA, Inc., New York, NY. Chapter 9, 2007.
• Hermsen ED, Rotschafer JC. Metronidazole and Other Antibiotics for Anaerobic Infections: A Focus on Resistance and Pharmacodynamics. In: Textbook of Critical Care, 5th edition. Editors: MP Fink, E Abraham, PM Kochanek, JL Vincent. W.B. Saunders, Philadelphia, PA. Chapter 147, 2005.
• Hermsen ED, Rotschafer JC. Central Nervous System Infections. In: Pharmacotherapy: A Pathophysiologic Approach, 6th edition. Editors: JT DiPiro, RL Talbert, GC Yee, GR Matzke, BG Wells, LM Posey. McGraw-Hill, Columbus, OH. Chapter 105, 2005.

Abstracts

• Fitzgerald T, Hermsen ED, Sholtz LA, Anderson JR, Iwen PC, Jourdan D, Marion N, Rupp ME. Multi-disciplinary Interventions for the Management and Prevention of Clostridium difficile-Associated Disease at an Academic Medical Center. Accepted abstract, Poster Presentation, Annual Conference of the Association for Professionals in Infection Control, Denver, CO, June 15 – June 19, 2008.
• Hermsen ED, Shull SS, Parizek L, Qiu F, Wilderman J, Rupp ME. Outcomes of a Pharmacist-Initiated Antimicrobial Step-Down Protocol. Accepted abstract, Poster Presentation, Annual Meeting of the American College of Clinical Pharmacy, Denver, CO, October 14 – October 17, 2007.
• Hermsen ED, Shull SS, Parizek L, Qiu F, Wilderman J, Rupp ME. Antimicrobial Step-Down Conversion on a General Medicine Ward. Accepted abstract, Oral Presentation, 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 4 – October 7, 2007.
• Hermsen ED, Shull SS, Klepser DG, Iwen PC, Armbrust A, Garrett J, Freifeld AG, Rupp ME. Pharmacoeconomic analysis of microbiologic techniques for differentiating Gram-positive cocci in clusters (GPCC) directly from blood culture bottles. Accepted abstract, Poster Presentation, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17 – September 20, 2007.
• Hermsen ED, Mitropoulos IF, Shull SS, Puumala S, Rupp ME. Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to Gram-positive cocci (GPC). Accepted abstract, Poster Presentation, 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12 – October 15, 2006.
• Hermsen ED, Shull SS, Puumala S, Rupp ME. Comparative evaluation of clinical and economic parameters of an antimicrobial surgical prophylaxis (ASP) order form. Accepted abstract, Poster Presentation, 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12 – October 15, 2006.
• Hermsen ED, Hovde LB, Peterson ML, Rotschafer JC. Activity of four fluoroquinolones against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae with a topoisomerase mutation in an in vitro pharmacodynamic model. Accepted abstract, Poster Presentation, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., December 16-December 19, 2005.
• Hermsen ED, Shull SS. Coagulase-Negative Staphylococci Contaminated Blood Cultures and Associated Costs. Accepted abstract, Poster Presentation, 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 6 – October 9, 2005.
• Hermsen ED, Hovde LB, Peterson ML, Rotschafer JC. Differences in activity among four fluoroquinolones against extended-spectrum beta-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an in vitro pharmacodynamic model. Accepted abstract, Poster Presentation, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., October 30-November 2, 2004.
• Hermsen ED, Hovde LB, Konstantinides GN, Rotschafer JC. Mutation prevention concentration of ABT-492 versus three fluoroquinolones against common respiratory pathogens. Accepted abstract, Poster Presentation, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., October 30-November 2, 2004.
• Hermsen ED, Hovde LB, Peterson ML, Rotschafer JC. Differences in activity among four fluoroquinolones against extended-spectrum beta-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an in vitro pharmacodynamic model. Accepted abstract, Poster Presentation, 11th International Congress on Infectious Diseases. Cancún, Mexico, March 4-7, 2004.
• Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased bacterial killing with daptomycin versus cefazolin and vancomycin against Staphylococci and Streptococci in peritoneal dialysate fluid. Accepted abstract, Poster Presentation, 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 14-17, 2003.
• Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased bacterial killing with daptomycin versus cefazolin and vancomycin against Staphylococci and Streptococci in peritoneal dialysate fluid. Accepted abstract, Poster Presentation, and Platform Presentation, 6th Annual International Conference of Infectious Diseases Pharmacotherapy. Orlando, FL, May 1-4, 2003.
• Hermsen ED, Hovde LB, Peterson ML, Rotschafer JC. In vitro pharmacodynamics of levofloxacin, ciprofloxacin, moxifloxacin, and gatifloxacin against two strains of Escherichia coli with decreased susceptibility to fluoroquinolones. Accepted abstract, Poster Presentation, 2nd Annual Infection Meeting: Maximizing the Probability of Positive Outcomes. Las Vegas, NV, April 23-26, 2003.